sphingotec is adding an advanced POC testing platform to portfolio SphingoTec GmbH will offer its next-generation sepsis, heart failure and acute kidney injury biomarkers penKid® and bio-ADM® on NEXUS IB 10 point-of-care (POC) testing platform, originally developed by Nexus Dx penKid® and bio-ADM® are first-in-class biomarkers to diagnose and monitor real-time kidney function and…Read more
Recent Posts by admin
Berlin (Germany) – Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more than 5 million US patients with congestive heart failure die every year from their condition. Other disorders…Read more
sphingotest® bio-ADM® Assay can help reduce re-admissions and death by measuring residual congestion. Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, and SphingoTec GmbH today announced a long-term, global strategic agreement regarding the endothelial function marker, biologically active Adrenomedullin (sphingotest® bio-ADM®), which measures patients’ rate of recovery from acute heart failure, providing…Read more
Researchers from other institutions can request to have their studies performed using these biomarkers. SphingoTec GmbH , a biotechnology company that develops biomarkers for the detection and management of diseases, has recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of several biomarkers that may improve the diagnosis of certain…Read more
Recent Comments by admin
No comments by admin yet.